ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Anlotinib induces apoptosis and second growth/mitosis phase block in cisplatin-resistant ovarian cancer cells via the aurora kinase A/p53 pathway

Wang, Hongli*; Wang, Yu哈尔滨医科大学
Human and Experimental Toxicology2023-6-17DOI: 10.1177/09603271231185774
1被引9阅读
引用收藏
分享

摘要

BackgroundCisplatin (DDP) resistance in ovarian cancer (OC) patients usually leads to treatment failure and increased mortality. Anlotinib has been shown to improve progression-free survival and overall survival in patients with platinum-resistant ovarian cancer, but the mechanism is unclear. This study aims to explore the mechanism by which anlotinib ameliorates platinum resistance in OC cells.MethodsCell viability was detected by the 3-4,5-dimethylthiazol-2,5-diphenyltetrazolium bromide (MTT) method, and the apoptosis rate and changes in the cell cycle distribution were evaluated by flow cytometry. Bioinformatics analysis was used to predict the potential gene target of anlotinib in DDP-resistance SKOV3 cells, and its expression was verifies it by RT-qPCR, western blotting and immunofluorescence staining. Finally, ovarian cancer cells overexpressing AURKA were constructed, and the predicted results were verified by animal experiments.ResultsAnlotinib effectively induced apoptosis and G2/M arrest in OC cells and decreased the proportion of EdU-positive cells. AURKA was identified as a possible key target of anlotinib for inhibiting tumorigenic behaviors in SKOV3/DDP cells. Through combined immunofluorescence and western blot analyses, it was demonstrated that anlotinib could effectively inhibit the protein expression of AURKA and upregulate the expression of p53/p21, CDK1, and Bax protein. After overexpression of AURKA in OC cells, the induction of apoptosis and G2/M arrest by anlotinib were significantly inhibited. Anlotinib also effectively inhibited the growth of tumors in nude mice injected with OC cells.ConclusionsThis study demonstrated that anlotinib can induce apoptosis and G2/M arrest in cisplatin-resistant ovarian cancer cells through the AURKA/p53 pathway.

学科与关键词

关键词
Ovarian cancerresistantanlotinibAURKAapoptosisphase
相关
加载中…
  • Novel Aurora A Kinase Inhibitor Fangchinoline Enhances Cisplatin-DNA Adducts and Cisplatin Therapeutic Efficacy in OVCAR-3 Ovarian Cancer Cells-Derived Xenograft Model
    Winardi, Daniel; Chu, Pei-Yi; Chen, Guan-Yu; Wang, Ke; Hsu, Wei-Yu; Hsieh, Ching-Liang; Chen, Yung-Hsiang; Wu, Yang-Chang*; Yang, Juan-Cheng*INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23(3): 1868.被引 5
  • Silencing of NLRP3 Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin
    Li, Weijia; Zhao, Xibo; Zhang, Rujian; Xie, Jiabin; Zhang, Guangmei*Mediators of Inflammation, 2023, 2023: 7700673.
  • Label-free-based quantitative proteomic analysis of the inhibition of cisplatin-resistant ovarian cancer cell proliferation by cucurbitacin B
    Yin, Shuanghong; Mai, Zhikai; Liu, Can; Xu, Lipeng*; Xia, Chenglai*PHYTOMEDICINE, 2023, 111: 154669.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Human and Experimental Toxicology
发表日期
2023-06-17
卷期
第 42 卷
页码
09603271231185774
DOI
10.1177/09603271231185774
语言
ENGLISH
成果收录
SCIE

作者

  • W

    Wang, Hongli (通讯) (第一作者)

    2 · harbin med univ

  • W

    Wang, Yu

    2 · harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417